OBJECTIVES: To determine prevalence and co-existence of myositis specific autoantibodies (MSAs) and myositis associated autoantibodies (MAAs) and associated clinical characteristics in a large cohort of idiopathic inflammatory myopathy (IIM) patients. METHODS: Adult patients with confirmed IIM recruited to the EuroMyositis registry (n = 1637) from four centres were investigated for the presence of MSAs/MAAs by radiolabelled-immunoprecipitation, with confirmation of anti-MDA5 and anti-NXP2 by ELISA. Clinical associations for each autoantibody were calculated for 1483 patients with a single or no known autoantibody by global linear regression modelling. RESULTS: MSAs/MAAs were found in 61.5% of patients, with 84.7% of autoantibody positive patients having a sole specificity, and only three cases (0.2%) having more than one MSA. The most frequently detected autoantibody was anti-Jo-1 (18.7%), with a further 21 specificities each found in 0.2-7.9% of patients. Autoantibodies to Mi-2, SAE, TIF1, NXP2, MDA5, PMScl and the non-Jo-1 tRNA-synthetases were strongly associated (p < 0.001) with cutaneous involvement. Anti-TIF1 and anti-Mi-2 positive patients had an increased risk of malignancy (OR 4.67 and 2.50 respectively), and anti-SRP patients had a greater likelihood of cardiac involvement (OR 4.15). Interstitial lung disease was strongly associated with the anti-tRNA synthetases, anti-MDA5, and anti-U1RNP/Sm. Overlap disease was strongly associated with anti-PMScl, anti-Ku, anti-U1RNP/Sm and anti-Ro60. Absence of MSA/MAA was negatively associated with extra-muscular manifestations. CONCLUSIONS: Myositis autoantibodies are present in the majority of patients with IIM and identify distinct clinical subsets. Furthermore, MSAs are nearly always mutually exclusive endorsing their credentials as valuable disease biomarkers.

Centre for Musculoskeletal Research The University of Manchester Manchester Academic Health Science Centre Manchester UK; National Institute of Health Research Manchester Biomedical Research Centre Manchester University Foundation Trust UK; Salford Royal NHS Foundation Trust Manchester UK

Centre for Musculoskeletal Research The University of Manchester Manchester Academic Health Science Centre Manchester UK; Salford Royal NHS Foundation Trust Manchester UK

Department of Internal Medicine University of Debrecen Debrecen Hungary

Department of Mathematics University of Exeter Exeter UK

Department of Pharmacy and Pharmacology University of Bath Bath UK

Division of Rheumatology Department of Medicine Solna Karolinska Institutet And Karolinska University Hospital Stockholm Sweden

Institute of Ageing and Chronic Disease University of Liverpool Liverpool UK

Institute of Rheumatology and Department of Rheumatology 1stMedical Faculty Charles University Prague Czech Republic

Zobrazit více v PubMed

Love L.A., Leff R.L., Fraser D.D., Targoff I.N., Dalakas M., Plotz P.H. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine. 1991 Nov;70(6):360–374. PubMed

Betteridge Z., McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J. Int. Med. 2016 Jul;280(1):8–23. PubMed

Muro Y., Sugiura K., Akiyama M. Cutaneous manifestations in dermatomyositis: key clinical and serological features-a comprehensive review. Clin. Rev. Allergy Immunol. 2016 Dec;51(3):293–302. PubMed

Gunawardena H. The clinical features of myositis-associated autoantibodies: a review. Clin. Rev. Allergy Immunol. 2017 Feb;52(1):45–57. PubMed

McHugh N.J., Tansley S.L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 2018 Apr 20;14(5):290–302. PubMed

Mariampillai K., Granger B., Amelin D., Guiguet M., Hachulla E., Maurier F. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and myositis-specific autoantibodies. JAMA Neurol. 2018 Dec 1;75(12):1528–1537. PubMed PMC

Svensson J., Arkema E.V., Lundberg I.E., Holmqvist M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology. 2017 May 01;56(5):802–810. PubMed

Bohan A., Peter J.B. Polymyositis and dermatomyositis (first of two parts) N. Engl. J. Med. 1975 Feb 13;292(7):344–347. PubMed

Bohan A., Peter J.B. Polymyositis and dermatomyositis (second of two parts) N. Engl. J. Med. 1975 Feb 20;292(8):403–407. PubMed

Lilleker J.B., Vencovsky J., Wang G., Wedderburn L.R., Diederichsen L.P., Schmidt J. The EuroMyositis registry: an international collaborative tool to facilitate myositis research. Ann. Rheum. Dis. 2018 Jan;77(1):30–39. PubMed PMC

Betteridge Z., Gunawardena H., North J., Slinn J., McHugh N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology. 2007 Jun;46(6):1005–1008. PubMed

Tansley S.L., Simou S., Shaddick G., Betteridge Z.E., Almeida B., Gunawardena H. Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort. J. Autoimmun. 2017 Nov;84:55–64. PubMed PMC

Tansley S.L., Betteridge Z.E., Gunawardena H., Jacques T.S., Owens C.M., Pilkington C. Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther. 2014 Jul 2;16(4):R138. PubMed PMC

Tansley S.L., Betteridge Z.E., Shaddick G., Gunawardena H., Arnold K., Wedderburn L.R. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology. 2014 Dec;53(12):2204–2208. PubMed PMC

R Development Core Team . R Foundation for Statisical Computing; Vienna, Austria: 2015. R: A Language and Environment for Statistical Computing.

Calcagno V., de Mazancourt C. Glmulti: an R package for easy automated model selection with (generalized) linear models. J. Stat. Softw. 2010 May;34(12):1–29.

Chen Z., Hu W., Wang Y., Guo Z., Sun L., Kuwana M. Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin. Rheumatol. 2015 Sep;34(9):1627–1631. PubMed

Rider L.G., Shah M., Mamyrova G., Huber A.M., Rice M.M., Targoff I.N. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine. 2013 Jul;92(4):223–243. PubMed PMC

O'Hanlon T.P., Carrick D.M., Targoff I.N., Arnett F.C., Reveille J.D., Carrington M. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine. 2006 Mar;85(2):111–127. PubMed

Cavazzana I., Fredi M., Ceribelli A., Mordenti C., Ferrari F., Carabellese N. Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J. Immunol. Meth. 2016 Jun;433:1–5. PubMed

Hamaguchi Y., Fujimoto M., Matsushita T., Kaji K., Komura K., Hasegawa M. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One. 2013;8(4) PubMed PMC

Tampoia M., Notarnicola A., Abbracciavento L., Fontana A., Giannini M., Louis Humbel R. A new immunodot assay for multiplex detection of autoantibodies in a cohort of Italian patients with idiopathic inflammatory myopathies. J. Clin. Lab. Anal. 2016 Nov;30(6):859–866. PubMed PMC

Fiorentino D.F., Kuo K., Chung L., Zaba L., Li S., Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1gamma antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 2015 Mar;72(3):449–455. PubMed PMC

La Corte R., Lo Mo Naco A., Locaputo A., Dolzani F., Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006 May;39(3):249–253. PubMed

Marie I., Hatron P.Y., Dominique S., Cherin P., Mouthon L., Menard J.F. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011 Nov;63(11):3439–3447. PubMed

Fiorentino D., Chung L., Zwerner J., Rosen A., Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J. Am. Acad. Dermatol. 2011 Jul;65(1):25–34. PubMed PMC

Rogers A., Chung L., Li S., Casciola-Rosen L., Fiorentino D.F. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 2017 Dec;69(12):1909–1914. PubMed PMC

Aggarwal R., Cassidy E., Fertig N., Koontz D.C., Lucas M., Ascherman D.P. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann. Rheum. Dis. 2014 Jan;73(1):227–232. PubMed PMC

Klein M., Mann H., Plestilova L., Betteridge Z., McHugh N., Remakova M. Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations. J. Rheumatol. 2014 Jun;41(6):1133–1139. PubMed

Qiang J.K., Kim W.B., Baibergenova A., Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J. Cutan. Med. Surg. 2017 Mar/Apr;21(2):131–136. PubMed

Trallero-Araguas E., Rodrigo-Pendas J.A., Selva-O'Callaghan A., Martinez-Gomez X., Bosch X., Labrador-Horrillo M. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012 Feb;64(2):523–532. PubMed

Fiorentino D.F., Chung L.S., Christopher-Stine L., Zaba L., Li S., Mammen A.L. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1gamma. Arthritis Rheum. 2013 Nov;65(11):2954–2962. PubMed PMC

Petri M.H., Satoh M., Martin-Marquez B.T., Vargas-Ramirez R., Jara L.J., Saavedra M.A. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res. Ther. 2013;15(2):R48. PubMed PMC

Hengstman G.J., Vree Egberts W.T., Seelig H.P., Lundberg I.E., Moutsopoulos H.M., Doria A. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann. Rheum. Dis. 2006 Feb;65(2):242–245. PubMed PMC

Ichimura Y., Matsushita T., Hamaguchi Y., Kaji K., Hasegawa M., Tanino Y. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis. 2012 May;71(5):710–713. PubMed

Troyanov Y., Targoff I.N., Payette M.P., Raynauld J.P., Chartier S., Goulet J.R. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features. Medicine. 2014 Nov;93(24):318–332. PubMed PMC

Yamasaki Y., Satoh M., Mizushima M., Okazaki T., Nagafuchi H., Ooka S. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod. Rheumatol. 2016 May;26(3):403–409. PubMed

Lundberg I.E. Cardiac involvement in autoimmune myositis and mixed connective tissue disease. Lupus. 2005;14(9):708–712. PubMed

Hengstman G.J., ter Laak H.J., Vree Egberts W.T., Lundberg I.E., Moutsopoulos H.M., Vencovsky J. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann. Rheum. Dis. 2006 Dec;65(12):1635–1638. PubMed PMC

Kao A.H., Lacomis D., Lucas M., Fertig N., Oddis C.V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 2004 Jan;50(1):209–215. PubMed

Marie I., Hatron P.Y., Hachulla E., Wallaert B., Michon-Pasturel U., Devulder B. Pulmonary involvement in polymyositis and in dermatomyositis. J. Rheumatol. 1998 Jul;25(7):1336–1343. PubMed

Kang E.H., Lee E.B., Shin K.C., Im C.H., Chung D.H., Han S.K. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology. 2005 Oct;44(10):1282–1286. PubMed

Fathi M., Lundberg I.E. Interstitial lung disease in polymyositis and dermatomyositis. Curr. Opin. Rheumatol. 2005 Nov;17(6):701–706. PubMed

Lega J.C., Fabien N., Reynaud Q., Durieu I., Durupt S., Dutertre M. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun. Rev. 2014 Sep;13(9):883–891. PubMed

Chen Z., Cao M., Plana M.N., Liang J., Cai H., Kuwana M. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care Res. 2013 Aug;65(8):1316–1324. PubMed

Kobayashi I., Okura Y., Yamada M., Kawamura N., Kuwana M., Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J. Pediatr. 2011 Apr;158(4):675–677. PubMed

Narang N.S., Casciola-Rosen L., Li S., Chung L., Fiorentino D.F. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease. Arthritis Care Res. 2015 May;67(5):667–672. PubMed PMC

Cavazzana I., Ceribelli A., Quinzanini M., Scarsi M., Airo P., Cattaneo R. Prevalence and clinical associations of anti-Ku antibodies in systemic autoimmune diseases. Lupus. 2008 Aug;17(8):727–732. PubMed

Lundberg I., Nyman U., Pettersson I., Hedfors E. Clinical manifestations and anti-(U1)snRNP antibodies: a prospective study of 29 anti-RNP antibody positive patients. Br. J. Rheumatol. 1992 Dec;31(12):811–817. PubMed

Rigolet A., Musset L., Dubourg O., Maisonobe T., Grenier P., Charuel J.L. Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease. Medicine. 2012 Mar;91(2):95–102. PubMed

Coppo P., Clauvel J.P., Bengoufa D., Oksenhendler E., Lacroix C., Lassoued K. Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome. Rheumatology. 2002 Sep;41(9):1040–1046. PubMed

Lundberg I.E., Tjarnlund A., Bottai M., Werth V.P., Pilkington C., de Visser M. 2017 european league against rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol. 2017 Dec;69(12):2271–2282. (Hoboken, NJ) PubMed PMC

Distinct HLA associations with autoantibody-defined subgroups in idiopathic inflammatory myopathies

Low copy numbers of complement C4 and C4A deficiency are risk factors for myositis, its subgroups and autoantibodies

Idiopathic inflammatory myopathies

Idiopathic inflammatory myopathies

Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis